Welcome to
Kinoxis Therapeutics

Harnessing the power of the social brain to develop novel treatments for social challenges and substance use disorders.

Welcome to
Kinoxis Therapeutics

Harnessing the power of the social brain to develop novel treatments for social challenges and substance use disorders.

Social Neuroscience Guided Therapeutics.

Social challenges are amongst the most pervasive symptoms across psychiatric and neurological disorders. Social behavior is complex and involves complex brain circuitry.

Dysregulation of this circuitry leads to pervasive social symptoms, like anger and aggression, and symptoms in related domains, like emotional disturbances and changes in motivation.

These symptoms isolate patients and make loved ones feel helpless

At Kinoxis Therapeutics, we are developing therapies with transdiagnostic potential to restore social behavior and treat related symptoms across many diseases and disorders, to make them more bearable. 

For patients and for loved ones.

Social Neuroscience Guided Therapeutics

Agitation & Aggression


Agitation and aggression are common to many disorders of the brain and mind and encompass a range of disruptive behaviours such as verbal outbursts, physically harmful actions, restlessness, repetitive behaviours, and excessive negativity. These symptoms can leave patients socially isolated and pose a major challenge for carers.

Substance Use Disorders


Millions of people worldwide suffer from substance use disorders, overdose deaths are on the rise, and one of the biggest obstacles to recovery is craving – an intense urge to use a substance, driven by neurobiological changes, that reinforces drug use and significantly increases the risk of relapse.

Clinical Trials


We are committed to developing safe and effective medicines as quickly as possible.
We recognise the importance of improving quality of life, for patients and their loved ones.


Kinoxis News

Kinoxis Secures $2.5M CUREator+ Grant to support CARES-X, a Phase 2a Clinical Study for Agitation in Dementia

Kinoxis Secures $2.5M CUREator+ Grant to Support CARES-X, A Phase 2a Australia-Based Clinical Study for KNX100 in Treating Agitation Associated with Dementia MELBOURNE, AUSTRALIA, 23 December 2024 – Kinoxis Therapeutics, an.

Series B
Kinoxis secures $14.5m in funding and announces expansion of clinical programs to target agitation and aggression in dementia patients

$14.5m Series B funding raised, with support from key investors Uniseed, UniSuper, University of Sydney, Stoic VC, Avicella Capital, as well as sophisticated investors..

NIAAA colab
Kinoxis Announces Plan to Evaluate KNX100 for the Treatment of Alcohol Use Disorder

KNX100 is a novel small molecule being developed as a transdiagnostic treatment for substance use disorders, including alcohol use disorder. A recently completed Phase.

NIDA funding
Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder

KNX100 is a small molecule in development for the treatment of substance use disorders, including symptoms associated with withdrawal from opioids US$3.6 million awarded.

The people of Kinoxis

Our team has diverse professional experience across the biotech ecosystem, with an established track record in drug development, clinical research, and strategic innovation, ensuring a holistic approach to advancing groundbreaking therapies and transforming patient outcomes.

Find out about our latest clinical trials